- Home
- SGA vs VRCA Comparison
SGA vs VRCA Comparison
Compare SGA & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | VRCA |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 87.5M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SGA | VRCA |
|---|---|---|
| Price | $11.97 | $4.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 7.8K | ★ 120.8K |
| Earning Date | 03-12-2026 | 03-11-2026 |
| Dividend Yield | ★ 8.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | $35,577,000.00 |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | N/A | $92.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.65 | ★ 370.22 |
| 52 Week Low | $10.68 | $0.39 |
| 52 Week High | $14.27 | $9.82 |
Technical Indicators
Market Signals| Indicator | SGA | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 31.13 |
| Support Level | $11.75 | $3.96 |
| Resistance Level | $11.99 | $4.87 |
| Average True Range (ATR) | 0.31 | 0.59 |
| MACD | 0.07 | -0.13 |
| Stochastic Oscillator | 85.22 | 5.40 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.